Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 21,878 shares at $8.35 ($186K) on 2019-06-10, disclosed to the SEC on 2019-06-11.
Open-market purchase of $186k UROV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.35 | 7,500 | $63K | 33.7% |
| 2 | $8.58 | 7,189 | $62K | 33.2% |
| 3 | $8.58 | 7,189 | $62K | 33.2% |
| Total | $8.50 avg | 21,878 | $186K | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $262K | — | Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| MYOV | BUY | 2019-06-06 | $40.0M | — | Filing → |